Epidemiology Seminar Zoom Meeting: Eric Ammann, Ph.D.
March 27, 2020
10:00 am-11:00 am
Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease.
There is limited evidence on the effectiveness and safety of direct-acting oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD). Patients with advanced CKD were generally excluded from the clinical trials supporting the approval of DOACs for NVAF, and clinical guidelines offer tentative and conflicting recommendations about the use of DOACs in this setting. The present observational retrospective cohort study compared the risks of ischemic stroke/systemic embolism (ISSE) and major bleeding in patients with NVAF and stage IV-V CKD treated with rivaroxaban or warfarin.
Eric Ammann, PhD, is Associate Director of Real World Research at Janssen Scientific Affairs, a subsidiary of Johnson & Johnson. He trained as a pharmacoepidemiologist at the University of Iowa.
Disclosures: Eric Ammann is an employee of Johnson & Johnson, Inc., which markets rivaroxaban.